Dolly A. Vance
Net Worth
Last updated:
What is Dolly A. Vance net worth?
The estimated net worth of Ms. Dolly A. Vance is at least $14,716,349 as of 18 Dec 2014. She owns shares worth $22,149 as insider and has received compensation worth at least $14,694,200 in Rigel Pharmaceuticals, Inc..
What is the salary of Dolly A. Vance?
Ms. Dolly A. Vance salary is $734,710 per year as Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec. in Rigel Pharmaceuticals, Inc..
How old is Dolly A. Vance?
Ms. Dolly A. Vance is 60 years old, born in 1965.
What stocks does Dolly A. Vance currently own?
As insider, Ms. Dolly A. Vance owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc. (RIGL) | Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec. | 575 | $38.52 | $22,149 |
What does Rigel Pharmaceuticals, Inc. do?
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Dolly A. Vance insider trading
Rigel Pharmaceuticals, Inc.
Ms. Dolly A. Vance has made 3 insider trades between 2005-2014, according to the Form 4 filled with the SEC. Most recently she sold 1,000 units of RIGL stock on 18 Dec 2014.
The largest trade she's ever made was exercising 15,000 units of RIGL stock on 10 May 2005. As of 18 Dec 2014 she still owns at least 575 units of RIGL stock.
Rigel Pharmaceuticals key executives
Rigel Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Wolfgang Dummer M.D., Ph.D. (59) Executive Vice President & Chief Medical Officer
- Mr. David A. Santos (62) Executive Vice President & Chief Commercial Officer
- Mr. Dean L. Schorno CPA (62) Executive Vice President & Chief Financial Officer
- Mr. Raul R. Rodriguez (64) Pres, Chief Executive Officer & Director
- Ms. Dolly A. Vance (60) Executive Vice President of Corporation Affairs, Gen. Counsel & Corporation Sec.